Capricor’s Deramiocel Shows Durable Benefits in Duchenne Muscular Dystrophy Trials — Capricor Therapeutics, Inc.

Event summary

Capricor to present five-year HOPE-2 OLE data and HOPE-3 Phase 3 results for Deramiocel at PPMD 2026 Annual Conference.
Deramiocel demonstrated durable skeletal and cardiac muscle benefits over five years in the HOPE-2 OLE study.
HOPE-3 Phase 3 trial met primary and key secondary endpoints with statistical significance.
Deramiocel maintained a favorable safety profile across both studies.
FDA target action date for Deramiocel BLA is August 22, 2026.

The big picture

Capricor’s positive data for Deramiocel comes at a critical time for rare disease therapeutics, where cell-based treatments are gaining traction. The durable benefits observed in both skeletal and cardiac muscle function position Deramiocel as a potential breakthrough in Duchenne Muscular Dystrophy treatment. With the FDA review underway, Capricor’s ability to navigate regulatory hurdles will be key to unlocking the therapy’s market potential.

What we're watching

Regulatory Approval: Whether the FDA will approve Deramiocel by the August 22, 2026 PDUFA target action date.
Market Potential: The pace at which Capricor can commercialize Deramiocel if approved, given its Orphan Drug and RMAT designations.
Clinical Validation: How the long-term durability of Deramiocel’s benefits will impact its adoption in the Duchenne Muscular Dystrophy treatment landscape.